NCT06237192 tests an MRD-adapted, non‑intensive regimen in adult Ph‑negative ALL. Key drugs: blinatumomab (bispecific T‑cell engager, CD3×CD19, immunotherapy) for MRD‑positive B‑ALL, redirecting patient T cells to kill CD19+ leukemic B cells, venetoclax (oral small‑molecule BH3 mimetic, BCL‑2 inhibitor) for MRD‑positive T‑ALL, blocking BCL‑2 to restore mitochondrial apoptosis in BCL‑2–dependent blasts (notably relevant to ETP‑like T‑ALL). Background chemo de‑intensified (no high‑dose MTX/ara‑C), prolonged L‑asparaginase, and serial intrathecal therapy. Targets/pathways: CD19 on B‑cell precursors with CD3 on T cells, the anti‑apoptotic BCL‑2 pathway, eradication of MRD‑defined leukemic clones to avoid allo‑HSCT if MRD negativity is achieved.